株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のヒトマイクロバイオーム(ヒト微生物叢)市場:適応症、技術(16SrRNA系統解析、メタゲノム解析)、治療分野、地域別 - 産業分析、市場規模、シェア、成長、動向、予測 2018年~2026年

Human Microbiome Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

発行 Transparency Market Research 商品コード 493949
出版日 ページ情報 英文 176 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
世界のヒトマイクロバイオーム(ヒト微生物叢)市場:適応症、技術(16SrRNA系統解析、メタゲノム解析)、治療分野、地域別 - 産業分析、市場規模、シェア、成長、動向、予測 2018年~2026年 Human Microbiome Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026
出版日: 2018年05月31日 ページ情報: 英文 176 Pages
概要

ヒトマイクロバイオーム(ヒト微生物叢)は、人間の口腔粘膜、唾液、消化管、結膜、皮膚などに存在する微生物叢で、現在、これらの微生物叢が免疫系や食物消化に及ぼす影響を明らかにすべく、幅広い研究が行われています。

当レポートでは、世界のヒトマイクロバイオーム(ヒト微生物叢)診断および治療薬市場を調査し、市場の概要、適応症・技術・治療分野・地域別の市場動向、市場規模の推移と予測、成長要因・阻害要因ならびに市場機会の分析、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 イントロダクション

  • 市場の定義と範囲
  • 市場セグメンテーション
  • 主な調査目的
  • 調査のハイライト

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー

第4章市場の概要

  • イントロダクション
    • 市場の定義
    • 産業の発展動向
  • 市場のダイナミクス
    • 促進要因
    • 阻害要因
    • 市場機会
  • ファイブフォース分析
  • 市場分析と予測
    • ヒトマイクロバイオーム診断市場の分析と予測
    • ヒトマイクロバイオーム治療薬市場の分析と予測
  • 市場の見通し
  • ヒトマイクロバイオーム治療薬:パイプライン概要
  • 規制シナリオ
  • ヒトマイクロバイオーム治療薬の現行治療法への影響力
  • 主なM&A事例

第5章 世界のヒトマイクロバイオーム診断市場:適応症別

  • 主な所見
  • イントロダクション
  • 市場規模の予測:適応症別
    • 消化器疾患・代謝異常症
    • 女性特有疾患
    • その他
  • 市場魅力分析:適応症別
  • 主な市場動向:適応症別

第6章 世界のヒトマイクロバイオーム診断市場:技術別

  • 主な所見
  • イントロダクション
  • 市場規模の予測:技術別
    • 16SrRNA系統解析
    • メタゲノム解析
  • 市場魅力分析:技術別
  • 主な市場動向:技術別

第7章 世界のヒトマイクロバイオーム治療薬市場:治療分野別

  • 主な所見
  • イントロダクション
  • 市場規模の予測:治療分野別
    • 消化器疾患
    • 代謝異常症
    • 女性特有疾患
    • 皮膚疾患
    • その他
  • 市場魅力分析:治療分野別
  • 主な市場動向:治療分野別

第8章 世界のヒトマイクロバイオーム診断・治療薬市場:地域別

  • イントロダクション
  • 市場規模の推移と予測:地域別
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力分析:地域別

第9章 北米

第10章 欧州

第11章 アジア太平洋

第12章 ラテンアメリカ

第13章 中東・アフリカ

第14章 競合情勢

  • 企業プロファイル
    • AO Biome LLC
    • Enterome Biosciences SA
    • Metabiomics Corp.
    • MicroBiome Therapeutics LLC
    • Osel, Inc.
    • Rebiotix, Inc.
    • uBiome, Inc.
    • Second Genome
    • Seres Therapeutics
    • Synthetic Biologics, Inc.
    • Vedanta Biosciences
    • その他の企業
図表

List of Tables

  • Table 1: Key Mergers and Acquisitions
  • Table 2: Global Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Indication, 2018-2026
  • Table 3: Global Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Technology, 2018-2026
  • Table 4: Global Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020-2026
  • Table 5: Global Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Region
  • Table 6: Global Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Region
  • Table 7: North America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Indication, 2018-2026
  • Table 8: North America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Technology, 2018-2026
  • Table 9: North America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Country, 2018-2026
  • Table 10: North America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020-2026
  • Table 11: North America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country, 2020-2026
  • Table 12: Europe Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Indication, 2018-2026
  • Table 13: Europe Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Technology, 2018-2026
  • Table 14: Europe Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Country, 2018-2026
  • Table 15: Europe Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020-2026
  • Table 16: Europe Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country, 2020-2026
  • Table 17: Asia Pacific Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Indication, 2018-2026
  • Table 18: Asia Pacific Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Technology, 2018-2026
  • Table 19: Asia Pacific Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Country, 2018-2026
  • Table 20: Asia Pacific Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020-2026
  • Table 21: Asia Pacific Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country, 2020-2026
  • Table 22: Latin America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Indication, 2018-2026
  • Table 23: Latin America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Technology, 2018-2026
  • Table 24: Latin America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Country, 2018-2026
  • Table 25: Latin America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020-2026
  • Table 26: Latin America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country, 2020-2026
  • Table 27: Middle East & Africa Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Indication, 2018-2026
  • Table 28: Middle East & Africa Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Technology, 2018-2026
  • Table 29: Middle East & Africa Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Country, 2018-2026
  • Table 30: Middle East & Africa Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020-2026
  • Table 31: Middle East & Africa Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country, 2020-2026

List of Figures

  • Figure 1: Global Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 2018-2026
  • Figure 2: Global Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 2020-2026
  • Figure 3: Human Microbiome Diagnostic Market Value Share by Indication (2018)
  • Figure 4: Human Microbiome Diagnostic Market Value Share by Technology (2018)
  • Figure 5: Human Microbiome Therapeutics Market Value Share by Therapeutic Area (2020)
  • Figure 6: Human Microbiome Therapeutics Market Value Share by Region (2020)
  • Figure 7: Global Human Microbiome Diagnostic Market Value Share Analysis, by Indication, 2018 and 2026
  • Figure 8: Global GI & Metabolic Disorders Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2026
  • Figure 9: Global Women's Health Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2026
  • Figure 10: Global Cancer Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2026
  • Figure 11: Global Others Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2026
  • Figure 12: Global Human Microbiome Diagnostic Market Attractiveness Analysis, by Indication, 2018
  • Figure 13: Global Human Microbiome Diagnostic Market Value Share Analysis, by Technology, 2018 and 2026
  • Figure 14: Global Human Microbiome Diagnostic Market Attractiveness Analysis, by Technology, 2018
  • Figure 15: Global Metagenomic Sequencing Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2026
  • Figure 16: Global 16s rRNA Sequencing Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2026
  • Figure 17: Global Human Microbiome Therapeutics Market Value Share Analysis, by Therapeutic Area, 2020 and 2026
  • Figure 18: Global GI Disorders Market Size (US$ Mn) and Y-o-Y Growth (%), 2020-2026
  • Figure 19: Global Metabolic Disorders Market Size (US$ Mn) and Y-o-Y Growth (%), 2020-2026
  • Figure 20: Global Women's Health Market Size (US$ Mn) and Y-o-Y Growth (%), 2020-2026
  • Figure 21: Global Skin Disorders Market Size (US$ Mn) and Y-o-Y Growth (%), 2020-2026
  • Figure 22: Global Others Market Size (US$ Mn) and Y-o-Y Growth (%), 2020-2026
  • Figure 23: Global Human Microbiome Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2020
  • Figure 24: Global Human Microbiome Diagnostics Market Value Share Analysis, by Region, 2018 and 2026
  • Figure 25: Global Human Microbiome Therapeutics Market Value Share Analysis, by Region, 2020 and 2026
  • Figure 26: Global Human Microbiome Diagnostics Market Attractiveness Analysis, by Region, 2018
  • Figure 27: Global Human Microbiome Therapeutics Market Attractiveness Analysis, by Region, 2020
  • Figure 28: North America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 2018-2026
  • Figure 29: North America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 2020-2026
  • Figure 30: North America Diagnostics Market Attractiveness Analysis, by Country, 2018
  • Figure 31: North America Therapeutics Market Attractiveness Analysis, by Country, 2020
  • Figure 32: North America Diagnostic Market Value Share Analysis, by Indication, 2018 and 2026
  • Figure 33: North America Diagnostic Market Value Share Analysis, by Technology, 2018 and 2026
  • Figure 34: North America Diagnostic Market Value Share Analysis, by Country, 2018 and 2026
  • Figure 35: North America Therapeutics Market Value Share Analysis by Therapeutic Area, 2020 and 2026
  • Figure 36: North America Therapeutics Market Value Share Analysis by Country, 2020 and 2026
  • Figure 37: North America Diagnostics Market Attractiveness Analysis, by Indication, 2018
  • Figure 38: North America Diagnostics Market Attractiveness Analysis, by Technology, 2018
  • Figure 39: North America Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2020
  • Figure 40: Europe Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 2018-2026
  • Figure 41: Europe Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 2020-2026
  • Figure 42: Europe Diagnostics Market Attractiveness Analysis, by Country, 2018
  • Figure 43: Europe Therapeutics Market Attractiveness Analysis, by Country, 2020
  • Figure 44: Europe Diagnostic Market Value Share Analysis, by Indication, 2018 and 2026
  • Figure 45: Europe Diagnostic Market Value Share Analysis, by Technology, 2018 and 2026
  • Figure 46: Europe Diagnostic Market Value Share Analysis, by Country, 2018 and 2026
  • Figure 47: Europe Therapeutics Market Value Share Analysis, by Therapeutic Area, 2020 and 2026
  • Figure 48: Europe Therapeutics Market Value Share Analysis, by Country, 2020 and 2026
  • Figure 49: Europe Diagnostics Market Attractiveness Analysis, by Indication, 2018
  • Figure 50: Europe Diagnostics Market Attractiveness Analysis, by Technology, 2018
  • Figure 51: Europe Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2020
  • Figure 52: Asia Pacific Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 2018-2026
  • Figure 53: Asia Pacific Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 2020-2026
  • Figure 54: Asia Pacific Diagnostics Market Attractiveness Analysis, by Country
  • Figure 55: Asia Pacific Therapeutics Market Attractiveness Analysis, by Country
  • Figure 56: Asia Pacific Diagnostic Market Value Share Analysis, by Indication, 2018 and 2026
  • Figure 57: Asia Pacific Diagnostic Market Value Share Analysis, by Technology, 2018 and 2026
  • Figure 58: Asia Pacific Diagnostic Market Value Share Analysis, by Country, 2018 and 2026
  • Figure 59: Asia Pacific Therapeutics Market Value Share Analysis, by Therapeutic Area, 2020 and 2026
  • Figure 60: Asia Pacific Therapeutics Market Value Share Analysis, by Country, 2020 and 2026
  • Figure 61: Asia Pacific Diagnostics Market Attractiveness Analysis, by Indication, 2018
  • Figure 62: Asia Pacific Diagnostics Market Attractiveness Analysis, by Technology, 2018
  • Figure 63: Asia Pacific Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2020
  • Figure 64: Latin America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 2018-2026
  • Figure 65: Latin America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 2020-2026
  • Figure 66: Latin America Diagnostics Market Attractiveness Analysis, by Country, 2018
  • Figure 67: Latin America Therapeutics Market Attractiveness Analysis, by Country, 2020
  • Figure 68: Latin America Diagnostics Market Value Share Analysis, by Indication, 2018 and 2026
  • Figure 69: Latin America Diagnostics Market Value Share Analysis, by Technology, 2018 and 2026
  • Figure 70: Latin America Diagnostics Market Value Share Analysis, by Country, 2018 and 2026
  • Figure 71: Latin America Therapeutics Market Value Share Analysis, by Therapeutic Area, 2020 and 2026
  • Figure 72: Latin America Therapeutics Market Value Share Analysis, by Country, 2020 and 2026
  • Figure 73: Latin America Diagnostics Market Attractiveness Analysis, by Indication, 2018
  • Figure 74: Latin America Diagnostics Market Attractiveness Analysis, by Technology, 2018
  • Figure 75: Latin America Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2020
  • Figure 76: Middle East & Africa Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 2018-2026
  • Figure 77: Middle East & Africa Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 2020-2026
  • Figure 78: Middle East & Africa Diagnostics Market Attractiveness Analysis, by Country, 2018
  • Figure 79: Middle East & Africa Therapeutics Market Attractiveness Analysis, by Country, 2020
  • Figure 80: Middle East & Africa Diagnostics Market Value Share Analysis, by Indication, 2018 and 2026
  • Figure 81: Middle East & Africa Diagnostics Market Value Share Analysis, by Technology, 2018 and 2026
  • Figure 82: Middle East & Africa Diagnostics Market Value Share Analysis, by Country, 2018 and 2026
  • Figure 83: Middle East & Africa Therapeutics Market Value Share Analysis, by Therapeutic Area, 2020 and 2026
  • Figure 84: Middle East & Africa Therapeutics Market Value Share Analysis, by Country, 2020 and 2026
  • Figure 85: MEA Diagnostics Market Attractiveness Analysis, by Indication, 2018
  • Figure 86: MEA Diagnostics Market Attractiveness Analysis, by Technology, 2018
  • Figure 87: MEA Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2020
目次

Title:
Human Microbiome Market (Indication - Gastrointestinal and Metabolic Disorders, Women's Health, Cancer; Technology - 16s rRNA Sequencing, Metagenomic Sequencing; Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Women's Health, Skin Disorders) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026.

Human Microbiome Market - Overview

Human microbiome, also known as microbiota, includes microbes such as fungi, bacteria, and virus. These microbes reside in oral mucosa, saliva, gastrointestinal tracts, conjunctiva, or on the surface or in deep layers of the skin. At present, extensive research is being conducted to discover the importance of these micro-organisms in maintaining immune systems and their contribution in digestion of food. Large number of microbes reside in the large intestine, with region of the human body having a distinct community of microbes dwelling. Studies are still in progress to understand factors regulating microbial colonization in the body that are just millimeters apart. The human microbiome project (HMP) was launched in 2008 as a U.S. National Institute of Health. This was initiated to identify and characterize microbes found in the healthy and diseases human body.

This report on the global human microbiome market analyzes the future prospects of the market. The market for diagnostics and therapeutics is independently analyzed as two separate markets within the report. The market for human microbiome therapeutics is segmented based on therapeutic area and region, while the market for human microbiome diagnostics is segmented in terms of indication, technology, and region. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research. A detailed qualitative analysis of factors driving and restraining the market and opportunities is provided in the market overview section. Market revenue in terms of US$ Mn for the period between 2018 and 2026 for diagnostics and 2020 to 2026 for therapeutics, along with the compound annual growth rate (CAGR %) from 2018/2020 to 2026 are provided for all the segments. Market related factors such as estimated launch of products, drugs in the pipeline, and industry-institute collaborations in research have been taken into consideration while estimating the market size. Growth rate for each segment within the global human microbiome market has been determined after a thorough analysis of past and present trends, demographics, future trends, technological developments, clinical trials, and regulatory requirements. These factors are projected to help market players to take strategic decisions to strengthen their positions and increase share in the global market.

Based on indication, the global human microbiome diagnostics market has been segmented into gastrointestinal and metabolic disorders, women's health, cancer, and others. The gastrointestinal & metabolic disorders segment is projected to expand at a considerable pace due to high unmet medical needs for gut health disorders and rise in population suffering from lifestyle-based metabolic diseases. In terms of technology, the market has been bifurcated into 16s rRNA sequencing and metagenomic sequencing. Both these forms have been documented to have various advantages and provide accurate testing and hence, these are likely to garner nearly equal share of the overall diagnostics market during the forecast period. Based on therapeutic area, the market has been segmented into gastrointestinal disorders, metabolic disorders, women's health, skin disorders, and others. The others segment includes autoimmune disorders, infant health disorders, and rare diseases.

In terms of region, the global human microbiome market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Additionally, the regions have been further segmented by major countries. These include the U.S., Canada, the U.K., Germany, China, Japan, Brazil, Mexico, the UAE, and South Africa. The competition landscape section included in the report is likely to assist existing players increase their market shares and new companies to establish their presence in the human microbiome market. The report profiles major players operating in the human microbiome market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include AOBiome LLC, Osel, Inc., Seres Therapeutics, Second Genome, uBiome, Inc., Metabiomics Corp., Rebiotix, Inc., and Vedanta Biosciences.

The global human microbiome market has been segmented as follows:

Global Human Microbiome Diagnostics Market, by Indication

  • Gastrointestinal and Metabolic Disorders
  • Women's Health
  • Cancer
  • Others

Global Human Microbiome Diagnostics Market, by Technology

  • 16s rRNA Sequencing
  • Metagenomic Sequencing

Global Human Microbiome Therapeutics Market, by Therapeutic Area

  • Gastrointestinal Disorders
  • Metabolic Disorders
  • Women's Health
  • Skin Disorders
  • Others

Global Human Microbiome Diagnostics and Therapeutics Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • UAE
    • South Africa
    • Rest of Middle East & Africa

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Human Microbiome Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Market Definition
    • 4.1.2. Industry Developments
  • 4.2. Market Dynamics
    • 4.2.1. Drivers
    • 4.2.2. Restraints
    • 4.2.3. Opportunity
  • 4.3. Porters Five Forces Analysis
  • 4.4. Global Human Microbiome Market Analysis and Forecasts
    • 4.4.1. Global Human Microbiome Diagnostics Market Analysis and Forecast, 2018-2026
    • 4.4.2. Global Human Microbiome Therapeutics Market Analysis and Forecast, 2020-2026
  • 4.5. Global Human Microbiome Market Outlook
  • 4.6. Human Microbiome Therapeutics: Pipeline Overview
  • 4.7. Regulatory Scenario
  • 4.8. Impact of human microbiome therapeutics on current treatment options
  • 4.9. Key Mergers and Acquisitions

5. Global Human Microbiome Diagnostics Market Analysis and Forecasts, by Indication

  • 5.1. Key Findings
  • 5.2. Introduction
  • 5.3. Market Size (US$ Mn) Forecast, by Indication
    • 5.3.1. Gastrointestinal and Metabolic Disorders
    • 5.3.2. Women's Health
    • 5.3.3. Cancer
    • 5.3.4. Others
  • 5.4. Market Attractiveness Analysis, by Indication, 2018
  • 5.5. Key Trends

6. Global Human Microbiome Diagnostics Market Analysis and Forecasts, by Technology

  • 6.1. Introduction
  • 6.2. Market Size (US$ Mn) Forecast, by Technology
    • 6.2.1. 16s rRNA Sequencing
    • 6.2.2. Metagenomic Sequencing
  • 6.3. Market Attractiveness Analysis, by Technology, 2018
  • 6.4. Key Developments

7. Global Human Microbiome Therapeutics Market Analysis and Forecasts, by Therapeutic Area

  • 7.1. Key Findings
  • 7.2. Introduction
  • 7.3. Market Size (US$ Mn) Forecast, by Therapeutic Area
    • 7.3.1. Gastrointestinal Disorders
    • 7.3.2. Metabolic Disorders
    • 7.3.3. Women's Health
    • 7.3.4. Skin Disorders
    • 7.3.5. Others
  • 7.4. Market Attractiveness Analysis, by Therapeutic Area, 2020
  • 7.5. Key Trends

8. Global Human Microbiome Market Analysis and Forecasts, by Region

  • 8.1. Introduction
  • 8.2. Market Size (US$ Mn) Forecast, by Region
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness Analysis, by Region,
    • 8.3.1. Global Human Microbiome Diagnostics Market (2018)
    • 8.3.2. Global Human Microbiome Therapeutics Market (2020)

9. North America Human Microbiome Market Analysis and Forecast

  • 9.1. Introduction
  • 9.2. Market Size (US$ Mn) Forecast, by Indication
    • 9.2.1. Gastrointestinal and Metabolic Disorders
    • 9.2.2. Women's Health
    • 9.2.3. Cancer
    • 9.2.4. Others
  • 9.3. Market Size (US$ Mn) Forecast, by Technology
    • 9.3.1. 16s rRNA Sequencing
    • 9.3.2. Metagenomic Sequencing
  • 9.4. Market Size (US$ Mn) Forecast, by Therapeutic Area
    • 9.4.1. Gastrointestinal Disorders
    • 9.4.2. Metabolic Disorders
    • 9.4.3. Women's Health
    • 9.4.4. Skin Disorders
    • 9.4.5. Others
  • 9.5. Market Size (US$ Mn) Forecast, by Country
    • 9.5.1. U.S.
    • 9.5.2. Canada
  • 9.6. Market Attractiveness Analysis, by Indication, 2018
  • 9.7. Market Attractiveness Analysis, by Technology, 2018
  • 9.8. Market Attractiveness Analysis, by Therapeutic Area, 2020
  • 9.9. Key Trends

10. Europe Human Microbiome Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Market Size (US$ Mn) Forecast, by Indication
    • 10.2.1. Gastrointestinal and Metabolic Disorders
    • 10.2.2. Women's Health
    • 10.2.3. Cancer
    • 10.2.4. Others
  • 10.3. Market Size (US$ Mn) Forecast, by Technology
    • 10.3.1. 16s rRNA Sequencing
    • 10.3.2. Metagenomic Sequencing
  • 10.4. Market Size (US$ Mn) Forecast, by Therapeutic Area
    • 10.4.1. Gastrointestinal Disorders
    • 10.4.2. Metabolic Disorders
    • 10.4.3. Women's Health
    • 10.4.4. Skin Disorders
    • 10.4.5. Others
  • 10.5. Market Size (US$ Mn) Forecast, by Country
    • 10.5.1. U.K.
    • 10.5.2. Germany
    • 10.5.3. Rest of Europe
  • 10.6. Market Attractiveness Analysis, by Indication, 2018
  • 10.7. Market Attractiveness Analysis, by Technology, 2018
  • 10.8. Market Attractiveness Analysis, by Therapeutic Area, 2020
  • 10.9. Key Trends

11. Asia Pacific Human Microbiome Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Market Size (US$ Mn) Forecast, by Indication
    • 11.2.1. Gastrointestinal and Metabolic Disorders
    • 11.2.2. Women's Health
    • 11.2.3. Cancer
    • 11.2.4. Others
  • 11.3. Market Size (US$ Mn) Forecast, by Technology
    • 11.3.1. 16s rRNA Sequencing
    • 11.3.2. Metagenomic Sequencing
  • 11.4. Market Size (US$ Mn) Forecast, by Therapeutic Area
    • 11.4.1. Gastrointestinal Disorders
    • 11.4.2. Metabolic Disorders
    • 11.4.3. Women's Health
    • 11.4.4. Skin Disorders
    • 11.4.5. Others
  • 11.5. Market Size (US$ Mn) Forecast, by Country
    • 11.5.1. China
    • 11.5.2. Japan
    • 11.5.3. Rest of Asia Pacific
  • 11.6. Market Attractiveness Analysis, by Indication, 2018
  • 11.7. Market Attractiveness Analysis, by Technology, 2018
  • 11.8. Market Attractiveness Analysis, by Therapeutic Area, 2020
  • 11.9. Key Trends

12. Latin America Human Microbiome Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Market Size (US$ Mn) Forecast, by Indication
    • 12.2.1. Gastrointestinal and Metabolic Disorders
    • 12.2.2. Women's Health
    • 12.2.3. Cancer
    • 12.2.4. Others
  • 12.3. Market Size (US$ Mn) Forecast, by Technology
    • 12.3.1. 16s rRNA Sequencing
    • 12.3.2. Metagenomic Sequencing
  • 12.4. Market Size (US$ Mn) Forecast, by Therapeutic Area
    • 12.4.1. Gastrointestinal Disorders
    • 12.4.2. Metabolic Disorders
    • 12.4.3. Women's Health
    • 12.4.4. Skin Disorders
    • 12.4.5. Others
  • 12.5. Market Size (US$ Mn) Forecast, by Country
    • 12.5.1. Brazil
    • 12.5.2. Mexico
    • 12.5.3. Rest of Latin America
  • 12.6. Market Attractiveness Analysis, by Indication, 2018
  • 12.7. Market Attractiveness Analysis, by Technology, 2018
  • 12.8. Market Attractiveness Analysis, by Therapeutic Area, 2020
  • 12.9. Key Trends

13. Middle East & Africa Human Microbiome Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Market Size (US$ Mn) Forecast, by Indication
    • 13.2.1. Gastrointestinal and Metabolic Disorders
    • 13.2.2. Women's Health
    • 13.2.3. Cancer
    • 13.2.4. Others
  • 13.3. Market Size (US$ Mn) Forecast, by Technology
    • 13.3.1. 16s rRNA Sequencing
    • 13.3.2. Metagenomic Sequencing
  • 13.4. Market Size (US$ Mn) Forecast, by Therapeutic Area
    • 13.4.1. Gastrointestinal Disorders
    • 13.4.2. Metabolic Disorders
    • 13.4.3. Women's Health
    • 13.4.4. Skin Disorders
    • 13.4.5. Others
  • 13.5. Market Size (US$ Mn) Forecast, by Country
    • 13.5.1. UAE
    • 13.5.2. South Africa
    • 13.5.3. Rest of Middle East & Africa
  • 13.6. Market Attractiveness Analysis, by Indication, 2018
  • 13.7. Market Attractiveness Analysis, by Technology, 2018
  • 13.8. Market Attractiveness Analysis, by Therapeutic Area, 2020
  • 13.9. Key Trends

14. Competition Landscape

  • 14.1. Company Profiles
    • 14.1.1. AO Biome LLC
      • 14.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.1.1.2. Recent Developments
      • 14.1.1.3. Product Portfolio
      • 14.1.1.4. SWOT Analysis
      • 14.1.1.5. Strategic Overview
    • 14.1.2. Enterome Biosciences SA
      • 14.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.1.2.2. Product Portfolio
      • 14.1.2.3. SWOT Analysis
      • 14.1.2.4. Strategic Overview
    • 14.1.3. Metabiomics Corp.
      • 14.1.3.1. Company Overview (HQ, business segments, employee strength)
      • 14.1.3.2. Product Portfolio
      • 14.1.3.3. SWOT Analysis
      • 14.1.3.4. Recent Developments
      • 14.1.3.5. Strategic Overview
    • 14.1.4. MicroBiome Therapeutics LLC
      • 14.1.4.1. Company Overview (HQ, business segments, employee strength)
      • 14.1.4.2. Product Portfolio
      • 14.1.4.3. SWOT Analysis
      • 14.1.4.4. Strategic Overview
      • 14.1.4.5. Recent Developments
    • 14.1.5. Osel, Inc.
      • 14.1.5.1. Company Overview (HQ, business segments, employee strength)
      • 14.1.5.2. Clinical Trial Candidates
      • 14.1.5.3. Product Portfolio
      • 14.1.5.4. SWOT Analysis
      • 14.1.5.5. Strategic Overview
    • 14.1.6. Rebiotix, Inc.
      • 14.1.6.1. Company Overview (HQ, business segments, employee strength)
      • 14.1.6.2. Product Portfolio
      • 14.1.6.3. SWOT Analysis
      • 14.1.6.4. Recent Developments
      • 14.1.6.5. Strategic Overview
    • 14.1.7. uBiome, Inc.
      • 14.1.7.1. Company Overview (HQ, business segments, employee strength)
      • 14.1.7.2. Recent Developments
      • 14.1.7.3. Product Portfolio
      • 14.1.7.4. SWOT Analysis
      • 14.1.7.5. Strategic Overview
    • 14.1.8. Second Genome
      • 14.1.8.1. Company Overview (HQ, business segments, employee strength)
      • 14.1.8.2. Financial Overview: Funding and Investments
      • 14.1.8.3. Product Portfolio
      • 14.1.8.4. SWOT Analysis
      • 14.1.8.5. Strategic Overview
    • 14.1.9. Seres Therapeutics
      • 14.1.9.1. Company Overview (HQ, business segments, employee strength)
      • 14.1.9.2. Product Portfolio
      • 14.1.9.3. Financial Overview
      • 14.1.9.4. SWOT Analysis
      • 14.1.9.5. Strategic Overview
    • 14.1.10. Synthetic Biologics, Inc.
      • 14.1.10.1. Company Overview (HQ, business segments, employee strength)
      • 14.1.10.2. Product Portfolio
      • 14.1.10.3. Financial Overview
      • 14.1.10.4. SWOT Analysis
      • 14.1.10.5. Strategic Overview
    • 14.1.11. Vedanta Biosciences
      • 14.1.11.1. Company Overview (HQ, business segments, employee strength)
      • 14.1.11.2. Product Portfolio
      • 14.1.11.3. Recent Developments
      • 14.1.11.4. SWOT Analysis
      • 14.1.11.5. Strategic Overview
    • 14.1.12. Others
      • 14.1.12.1. Metabogen AB
      • 14.1.12.2. Becton Dickinson & Company
      • 14.1.12.3. Evelo Biosciences
      • 14.1.12.4. ARTPred
      • 14.1.12.5. MaaT Pharma
      • 14.1.12.6. Blue Turtle Bio Technologies
      • 14.1.12.7. Axial Therapeutics
      • 14.1.12.8. Whole Biome
      • 14.1.12.9. 4D Pharma
      • 14.1.12.10. Symbiotix Therapies
      • 14.1.12.11. Phi Therapeutics
      • 14.1.12.12. Synlogic
      • 14.1.12.13. Biospherex LLC
Back to Top